Overview
Hypertrophic cardiomyopathy (HCM) is a common heart condition characterized by abnormal thickening of the heart muscle, particularly in the left ventricle. This thickening, also known as hypertrophy, can lead to impaired heart function, reduced blood flow, and increased risk of sudden cardiac death. HCM is a genetic disorder, meaning it is inherited from one's parents, and affects approximately 1 in 500 people worldwide. The condition can manifest at any age, from childhood to adulthood, and may be asymptomatic or present with symptoms such as chest pain, shortness of breath, and fatigue.
History/Background
The first descriptions of HCM date back to the early 20th century, but it wasn't until the 1960s that the condition was formally recognized as a distinct entity. In 1967, the American Heart Association (AHA) published a report highlighting the importance of HCM as a cause of sudden cardiac death in young athletes. Since then, significant advances have been made in understanding the genetic and molecular mechanisms underlying HCM, as well as the development of diagnostic and treatment strategies. Today, HCM is recognized as a leading cause of sudden cardiac death in young people, accounting for approximately 25% of all cases.
Key Information
HCM is caused by mutations in genes that code for proteins involved in the regulation of cardiac muscle contraction and relaxation. The most common genes associated with HCM are MYBPC3, MYH7, and TNNT2. The condition can be diagnosed through a combination of clinical evaluation, electrocardiogram (ECG), echocardiogram, and cardiac magnetic resonance imaging (MRI). Treatment options for HCM depend on the severity of symptoms and the presence of complications, such as arrhythmias or heart failure. Medications, such as beta blockers and anti-arrhythmics, may be prescribed to manage symptoms and prevent complications. In severe cases, implantable cardioverter-defibrillators (ICDs) or heart transplantation may be necessary.
Significance
HCM is a significant public health concern due to its high prevalence and potential for life-threatening complications. Early detection and treatment can significantly improve outcomes, but many cases remain undiagnosed or misdiagnosed. The development of genetic testing and advanced imaging techniques has improved diagnosis and management of HCM, but more research is needed to understand the underlying mechanisms and develop effective treatments. The AHA and other organizations have established guidelines for the diagnosis and treatment of HCM, emphasizing the importance of early detection and referral to specialized care.
